Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ARVN

ARVN - Arvinas Inc Stock Price, Fair Value and News

$12.94-0.68 (-4.99%)
Market Closed

56/100

ARVN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

56/100

ARVN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$13.42

Target 3M

$13.02

Target 6M

$13.15

ARVN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ARVN Price Action

Last 7 days

2.7%

Last 30 days

8.7%

Last 90 days

30.3%

Trailing 12 Months

-27.8%

ARVN RSI Chart

ARVN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ARVN Valuation

Market Cap

831.1M

Price/Earnings (Trailing)

-14.21

Price/Sales (Trailing)

2.66

EV/EBITDA

-13.21

Price/Free Cashflow

-2.52

ARVN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$13.42

Target 3M

$13.02

Target 6M

$13.15

ARVN Fundamentals

ARVN Revenue

Revenue (TTM)

312.3M

Rev. Growth (Yr)

-59.08%

Rev. Growth (Qtr)

87.05%

ARVN Earnings

Earnings (TTM)

-58.5M

Earnings Growth (Yr)

28.66%

Earnings Growth (Qtr)

42.65%

ARVN Profitability

EBT Margin

-18.78%

Return on Equity

-10.36%

Return on Assets

-6.93%

Free Cashflow Yield

-39.65%

ARVN Investor Care

Buy Backs (1Y)

6.53%

Diluted EPS (TTM)

-0.81

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025426.9M372.8M312.3M0
2024124.7M170.9M217.2M263.4M
2023137.3M158.1M159.4M78.5M
202274.5M102.8M126.8M131.3M
202125.2M24.9M26.6M53.5M
202045.2M46.9M24.5M25.9M
201914.2M14.8M41.5M43.0M
201810.0M11.7M13.5M14.3M
20170007.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Arvinas Inc

ARVN
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
 CEO
 WEBSITEarvinas.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES415

Arvinas Inc Frequently Asked Questions

ARVN is the stock ticker symbol of Arvinas Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Arvinas Inc is 831.06 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ARVN's fair value in chart for subscribers.

The fair value guage provides a quick view whether ARVN is over valued or under valued. Whether Arvinas Inc is cheap or expensive depends on the assumptions which impact Arvinas Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARVN.

As of Wed Jan 28 2026, ARVN's PE ratio (Price to Earnings) is -14.21 and Price to Sales (PS) ratio is 2.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARVN PE ratio will change depending on the future growth rate expectations of investors.